A unique portal, offering oncologists access to the latest information in the field of cancer research, will be launched in 2011 by the European Society for Medical Oncology (ESMO) in association with Thomson Reuters. The announcement was made today at the 35th ESMO Congress taking place from 8 to 12 October, in Milan, Italy.
Prof David J Kerr, President of ESMO, presented the Society’s latest project at the Opening Press Conference. “ESMO is the leading European professional organization for oncologists,” declared Professor Kerr. “We strive to serve our members and this year we are particularly excited about the launch of OncologyPRO. OncologyPRO stands for Oncology Professional Resources Online and is a unique scientific portal for ESMO members, providing instant access to the highest quality scientific knowledge in one easy-to-access portal. ESMO is proud to announce an exclusive partnership with Thomson Reuters, the world’s largest information provider, to create the site, which gives cancer specialists access to the most complete resources in oncology today.”
“First-class online resources for members are essential for knowledge-based societies and we are delighted to provide ESMO members with such a resource in OncologyPRO, our new state-of-the-art web site,” said Mr. Alan Howard, ESMO CEO. “ESMO has listened to its members and carefully evaluated their needs, both in the clinical and research settings. OncologyPRO provides a variety of services, far beyond the level of service an individual society could provide, thanks to our partnership with the Thomson Reuters organization. We are confident this service will be highly appreciated by our members.”
“OncologyPRO is an innovative collaboration between ESMO and Thomson Reuters that gives practicing clinicians an information portal tailored to meet their specific needs,” added Jon Brett-Harris, Executive Vice President at Thomson Reuters. “We’re delighted that our most up-to-date and clinically relevant content will be offered in a way that enables ESMO members to work more efficiently and ultimately to the benefit of patient outcomes.”
Source: European Society for Medical Oncology